|
|
|
|
Available: Yes* |
This title does not qualify for any discount. |
|
Other formats:
|
Edition: | 22th |
Publisher: | Jones & Bartlett Publishing |
ISBN: | 1-284-14351-1 (1284143511) |
ISBN-13: | 978-1-284-14351-5 (9781284143515) |
Format: | Handbook |
Binding: | E E Book + ProQuest Ebook Central |
Copyright: | 2018 |
Publish Date: | 12/17 |
Volume: | 2018 |
Weight: | 0.00 Lbs. |
Subject Class: | RET (Returns) |
Remarks: | A New Edition of this Title is Available |
Brandon Hill: | This is a Brandon Hill Title |
Return Policy: | Non-Returnable. |
|
|
ProQuest Ebook Central�: |
Please sign in to preview this title
|
|
|
|
ISSN Series: | Oncology Nursing Drug Handbook | Discipline: | + Nursing | Subject Definition: | Neoplasms-Nursing-Handbooks: Drug Therapy | NLM Class: | WY 49 | LC Class: | RC271 | Abstract: | Written especially for nurses caring for patients with cancer, the 2018 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2018 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs. New drugs include: avelumab (Bavencio), brigatinib (Alunbrig), durvalumab (Imfinzi), enasidenib (Idhifa), metronidazole hydrochloride (Flagyl), midostaurin (Rydapt), neratinib (Nerlynx), niraparib (Zejula), olaratumab (Lartruvo), ribociclib (Kisqali), rituximab and hyaluronidase human injection (Rituxan Hycela injection), rucaparib (Rubraca), telotristat ethyl (Xermelo), and tisagenlecleucel (Kymriah). |
|
* Subject to ProQuest Ebook Central� availability |
|
|
|
|
|
Follow Matthews Book Co. on:
Copyright © 2001-2024 Matthews Book Company - All rights reserved. - 11559 Rock Island Ct., Maryland Heights, MO, 63043 - (800) MED-BOOK
Matthews